NASDAQ:ELAB Elevai Labs (ELAB) Stock Price, News & Analysis $0.02 -0.01 (-33.22%) (As of 11/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Elevai Labs Stock (NASDAQ:ELAB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Elevai Labs alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.03▼$0.3552-Week Range$0.02▼$4.24Volume253.24 million shsAverage Volume10.00 million shsMarket Capitalization$418,180.50P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewElevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Read More… This is treason (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Elevai Labs Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks14th Percentile Overall ScoreELAB MarketRank™: Elevai Labs scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Elevai Labs.Read more about Elevai Labs' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elevai Labs is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elevai Labs is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElevai Labs has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Elevai Labs' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.28% of the float of Elevai Labs has been sold short.Short Interest Ratio / Days to CoverElevai Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevai Labs has recently increased by 172.44%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElevai Labs does not currently pay a dividend.Dividend GrowthElevai Labs does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.28% of the float of Elevai Labs has been sold short.Short Interest Ratio / Days to CoverElevai Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elevai Labs has recently increased by 172.44%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News SentimentN/A News SentimentElevai Labs has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Elevai Labs this week, compared to 1 article on an average week.Search Interest7 people have searched for ELAB on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Elevai Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elevai Labs insiders have not sold or bought any company stock.Percentage Held by Insiders37.00% of the stock of Elevai Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.22% of the stock of Elevai Labs is held by institutions.Read more about Elevai Labs' insider trading history. Receive ELAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevai Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address ELAB Stock News HeadlinesElevai Labs Inc. Announces Update and Extension of Pending Offer to ExchangeNovember 4 at 8:00 PM | markets.businessinsider.comElevai Labs Inc. Announces Update and Extension of Pending Offer to ExchangeNovember 4 at 5:45 PM | globenewswire.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 4, 2024 | Crypto 101 Media (Ad)Elevai Labs, Inc. (NASDAQ:ELAB) Sees Large Increase in Short InterestOctober 28, 2024 | americanbankingnews.comElevai Labs (NASDAQ: ELAB) Enters Master Services Agreement with KCRN Research, Inc.October 28, 2024 | americanbankingnews.comElevai Biosciences highlights past preclinical data on EL-32October 22, 2024 | markets.businessinsider.comElevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of ObesityOctober 22, 2024 | globenewswire.comElevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of ObesityOctober 21, 2024 | globenewswire.comSee More Headlines ELAB Stock Analysis - Frequently Asked Questions How have ELAB shares performed this year? Elevai Labs' stock was trading at $1.8282 at the beginning of the year. Since then, ELAB shares have decreased by 98.9% and is now trading at $0.0201. View the best growth stocks for 2024 here. How were Elevai Labs' earnings last quarter? Elevai Labs, Inc. (NASDAQ:ELAB) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.08) EPS for the quarter. The firm earned $0.61 million during the quarter. Elevai Labs had a negative trailing twelve-month return on equity of 216.19% and a negative net margin of 191.96%. When did Elevai Labs IPO? Elevai Labs (ELAB) raised $6 million in an initial public offering (IPO) on Tuesday, November 21st 2023. The company issued 1,500,000 shares at a price of $4.00 per share. Univest Securities acted as the underwriter for the IPO. How do I buy shares of Elevai Labs? Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Elevai Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elevai Labs investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII). Company Calendar Last Earnings8/14/2024Today11/04/2024Next Earnings (Estimated)12/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELAB Previous SymbolNASDAQ:ELAB CUSIPN/A CIK1840563 Webelevaiskincare.com Phone866-794-4940FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,300,000.00 Net Margins-191.96% Pretax Margin-191.92% Return on Equity-216.19% Return on Assets-118.16% Debt Debt-to-Equity Ratio0.19 Current Ratio1.05 Quick Ratio0.54 Sales & Book Value Annual Sales$2.47 million Price / Sales0.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book0.09Miscellaneous Outstanding Shares20,805,000Free Float13,107,000Market Cap$418,180.50 OptionableN/A BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:ELAB) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevai Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elevai Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.